Lab Seeks Approval to Import Controlled Drugs
Published Date: 9/12/2025
Notice
Summary
Cambridge Isotope Laboratories, Inc. wants to get official approval to import certain controlled substances. This means they’ll be allowed to bring in specific drugs for research or medical use. If approved, it could affect how these substances are handled and tracked, with no immediate cost changes announced.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Importer Registration Request for Controlled Substances
Cambridge Isotope Laboratories, Inc. applied to be registered as an importer of certain basic classes of controlled substances. If approved, the company would be allowed to import specific drugs for research or medical use. The notice says this could affect how those substances are handled and tracked, and it states there are no immediate cost changes announced.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-17579, Notice of Public Meeting of the Louisiana Advisory Committee to the U.S. Commission on Civil Rights
The Louisiana Advisory Committee to the U.S. Commission on Civil Rights is holding four Zoom meetings from October 2025 to February 2026 to talk about how coroners handle involuntary mental health commitments in Louisiana. These meetings affect anyone interested in civil rights and mental health policies in the state. The committee will listen to testimony, discuss findings, draft a report, and then vote on it—no money changes, just important decisions coming soon!
Next: 2025-17581, Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions, LLC wants to officially import certain controlled substances. This means they’re asking the government’s permission to bring in these special drugs safely and legally. If approved, it could affect companies and patients relying on these medicines, with no immediate cost changes announced.